Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05763511

Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
University of Aarhus · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy. We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses. Specifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm. The mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored. Analyses of blood and tissue samples will be used to examine the disease development and biology. Blood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.

Conditions

Timeline

Start date
2022-07-01
Primary completion
2024-12-04
Completion
2029-05-04
First posted
2023-03-10
Last updated
2024-05-09

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05763511. Inclusion in this directory is not an endorsement.

Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker (NCT05763511) · Clinical Trials Directory